[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"motion-sickness\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:motion-sickness":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,40,72],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100639763","motion-sickness-severity-and-sensorimotor-performance-100639763",false,"NCT07619469","Motion Sickness Severity and Sensorimotor Performance","The Relationship of Balance, Proprioception, Coordination, and Reaction Time Measurements With Motion Sickness Severity in Individuals With Motion Sickness: A Cross-Sectional Study","Inclusion Criteria:\n\n* Individuals aged between 18 and 40 years.\n* Diagnosed with motion sickness according to the Motion Sickness -Susceptibility Questionnaire Short Form (MSSQ-SF).\n* Normal hearing acuity.\n* No history of acute or chronic vestibular disease, other than motion sickness.\n* Normal or corrected-to-normal vision.\n* Adequate physical capability to fully perform the measurement protocols, including balance, proprioception, coordination, and reaction time tests.\n\nExclusion Criteria:\n\n* Presence of any physical or orthopedic problem that could interfere with testing.\n* History of acute or chronic instability, unsteadiness, or vertigo.\n* Severe visual impairment.\n* History of prior ear surgery.\n* Presence of any neurological condition or disorder.\n* History of migraines.\n* Current use of medications that could affect balance or vestibular function (e.g., vestibular suppressants, sedatives).\n* Use of alcohol or psychoactive substances within the last 48 hours prior to testing.","ALL","18 Years","40 Years",{"count":20,"type":21},41,"ESTIMATED","OBSERVATIONAL","Background: Motion sickness (MS) is a common syndrome characterized by autonomic and behavioral symptoms, such as nausea and dizziness, resulting from exposure to motion stimuli. Its pathophysiology is closely linked to sensory conflict and postural instability theories. While previous studies suggest that postural control, proprioception, and reaction times are affected in individuals susceptible to MS, there is a lack of comprehensive, comparative research evaluating all these parameters concurrently within the same cohort using standardized methods. Objective: This study aims to systematically measure balance, proprioceptive sensitivity, coordination, and reaction time parameters, and quantitatively analyze their relationship with motion sickness severity. Methodology: In this prospective, cross-sectional study, at least 41 participants aged 18-40 with motion sickness will be recruited. Participants will undergo motion sickness susceptibility and severity grading using the Motion Sickness Susceptibility Questionnaire Short Form (MSSQ-SF) and the Graybiel Scale. Objective assessments will include static and dynamic balance testing (ProKin®), knee joint position sense (Clinometer app), manual dexterity and dynamic balance coordination (Nine-Hole Peg Test, Tandem Walk, Romberg Test), and upper\u002Flower extremity reaction time measurements (BlazePod system).",[25,26,27],"Motion Sickness","Somatosensory Disorders","Dizziness","NOT_YET_RECRUITING","2026-06-23",{"date":31,"type":32},"2026-06-26","ACTUAL",{"date":34,"type":21},"2026-06-01",{"date":36,"type":21},"2026-08-05",{"name":38,"class":39},"Istinye University","OTHER",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":48,"sex":16,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":71},"100487074","stableeyes-with-active-neurofeedback-100487074","NCT05622344","StableEyes With Active Neurofeedback","StableEyes With Active Neurophysiological Feedback","SWAN","Inclusion Criteria:\n\n1. Provision of signed and dated informed consent form\n2. Stated willingness to comply with all study procedures and availability for the duration of the study\n3. In good general health as evidenced by medical history or diagnosed with unilateral vestibular schwannoma\n4. Willing to adhere to the SWAN and\u002For vestibular rehabilitation regimen\n\nExclusion Criteria:\n\n1. Current use of anti-nausea medication\n2. Presence of cervical spine pathology that limits head motion to \\\u003C 30 degrees in the horizontal or vertical plane (i.e. degenerative disc disease, rheumatoid arthritis)\n3. Any orthopedic pathology that prevents walking or standing independently (i.e. recent surgery)\n4. Legal blindness (20\u002F200 or worse visual acuity)\n5. Treatment using a motion sickness investigational drug or other motion sickness behavioral intervention within 30 days",true,"21 Years","70 Years",{"count":52,"type":21},48,"INTERVENTIONAL",[55],"NA","The investigators have developed a self-administered rehabilitation tool that incrementally guides the user to increase head motion to mitigate motion sickness and enhance postural recovery following centrifugation or unilateral vestibular nerve deafferentation surgery.",[58,59,60,25],"Vestibular Disorder","Vestibular Schwannoma","Space Motion Sickness","RECRUITING","2025-11-06",{"date":64,"type":32},"2025-11-10",{"date":66,"type":32},"2022-08-08",{"date":68,"type":21},"2026-09-30",{"name":70,"class":39},"Johns Hopkins University",2,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":48,"sex":16,"minAge":17,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":53,"phases":82,"briefSummary":83,"conditions":84,"keywords":85,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":119},"100584668","evaluation-of-a-device-to-reduce-motion-sickness-and-spatial-disorientation-100584668","NCT06892340","Evaluation of a Device to Reduce Motion Sickness and Spatial Disorientation","A Non-Invasive, Non-Sedating Device to Mitigate Motion Sickness and Spatial Disorientation","* Inclusion Criteria:\n\n  1. Healthy males and non-pregnant females between the ages of 18-50 who do not experience symptoms of motion sickness.\n  2. Participants who are English speaking.\n  3. Participants who are able to read and understand study procedures in order to provide informed consent.\n* Exclusion Criteria:\n\n  1. Females who are pregnant\n  2. Cardiac pathology (congestive heart failure, history of myocardial infarction, cardiac stent placement, pacemaker placement, heart surgery)\n  3. Hypertension requiring daily medication\n  4. Active vestibular disease to include Meniere's disease, migraine associated vertigo, benign paroxysmal positional vertigo, labyrinthitis\n  5. Neck pain or spinal pathology\n  6. Medications impacting cardiac, vestibular, or neurologic function\n  7. Recently ill or hospitalized within 30 days\n  8. Pilots and individuals formally desensitized to motion sickness\n  9. Use of vestibular suppressing medications or drugs within 24 hours of the study (antihistamines, histamine-1 receptor agonists, benzodiazepines, anticholinergics, dopamine receptor agonists, alcohol, marijuana, tobacco, opiates)\n  10. Participant has a history of epileptic seizures\n  11. Participant has a history of neurological diseases or traumatic brain injury\n  12. Abnormal vital signs obtained during pre-experimentation phase:\n* Heart Rate \\>100 or \\\u003C50\n* Systolic blood pressure \\>150 or \\\u003C90\n* Respiratory rate \\>24 or \\\u003C8 13. Participant has presence of devices, e.g., pacemakers, cochlear prosthesis, neurostimulators 14. Participant has abnormal ear anatomy or ear infection present 15. Participant has any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial","50 Years",{"count":81,"type":21},36,[55],"The purpose of this research study is to learn how a wearable nerve stimulation device, the Spark Biomedical's Sparrow Ascent System™, impacts the development of spatial disorientation and\u002For motion sickness in a healthy population.\n\nSpatial disorientation is when there is a \"mismatch\" between where a person is, and where the sense organs in their body tell them where they are. These sense organs include the inner ear (the vestibular system), the eyes (the visual system), the sense of where one's legs, back, and neck are (proprioceptive system), and one's higher thinking (cognitive centers). If spatial disorientation is severe or occurs in motion-naïve individuals, spatial disorientation can lead to motion sickness.\n\nThe Sparrow Ascent System™ is a wearable, battery-operated transcutaneous auricular (ear) neurostimulation (tAN) device. This means that it uses electrical pulses to stimulate branches of nerves on and\u002For around the ear, specifically the \"vagus\" and \"trigeminal\" nerves. These nerves are also responsible for your sensation of nausea and your heart rate (vagus nerve), as well as headaches (trigeminal nerve). The Sparrow System utilizes a flexible earpiece with embedded hydrogel electrodes that stick to the skin, the earpiece is disposable after use. This device is already Food and Drug Administration (FDA) approved for use in humans and is safely used for control of symptoms in a variety of other medical conditions, such as opioid withdrawal and acute stress reaction. In this study, we will determine if the Sparrow Ascent System™ impacts the development of spatial disorientation or motion sickness.",[25],[25,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108],"Simulator Sickness","Trigeminal innervation","Transcutaneous auricular neurostimulation","Sparrow Ascent","Neuromodulation","Simulator adaption syndrome","Transcutaneous vagus nerve stimulation","Auricle","Mild electrical stimulation","Cranial nerves","Occipital nerves","Cymba Concha","Afferent sensory innervation","Vagus Nerve","Auriculotemporal nerve","Trigeminal nerve","Auricular nerve","Cranial nerve V","Cranial nerve VII","Cranial nerve IX","Cranial nerve X","Non-invasive","Non-sedating","2025-08-12",{"date":111,"type":32},"2025-08-15",{"date":113,"type":32},"2025-02-21",{"date":115,"type":21},"2025-10-31",{"name":117,"class":118},"59th Medical Wing","FED",1]